The effects of cyclic adenosine monophosphate (cAMP) and atorvastatin on macrophage adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1)-mediated cholesterol efflux were investigated in a diabetic animal model. Golden hamsters were fed a high-fat diet which resulted in insulin resistance. Diabetes was induced by a single intraperitoneal injection of streptozotocin (30 mg/kg). Normal golden hamsters were used as controls. Peritoneal macrophages were incubated with apolipoprotein A-1 (apoA-1), 8-bromoadenosine-3′,5′-cyclic monophosphate (8-br-cAMP), and atorvastatin in vitro Intracellular cholesterol accumulation was greater in the diabetic animals than in the insulin-resistant animals. Expression of ABCA1 mRNA in macrophages from diabetic animals was upregulated by 8-br-cAMP and atorvastatin. ApoA-1 caused a time-dependent cellular cholesterol efflux. Both atorvastatin and 8-br-cAMP significantly facilitated ABCA1-mediated cellular cholesterol efflux, with the maximal cholesterol efflux rate observed in the macrophages from diabetic animals. Accumulation of cholesterol in the macrophages of diabetic animals can be significantly alleviated by atorvastatin or 8-br-cAMP through improving ABCA1-mediated cellular cholesterol efflux.
GordonTCastelliWPHjortlandMC: High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med1977; 62: 707–714.
2.
AssmannGSchulteH: Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol1992; 70: 733–737.
3.
LucGBardJMFerrièresJ: Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: The PRIME study. Arterioscler Thromb Vasc Biol2002; 22: 1155–1161.
4.
GwynneJT: High-density lipoprotein cholesterol levels as a marker of reverse cholesterol transport. Am J Cardiol1989; 64: 10G–17G.
5.
YanceyPGBortnickAEKellner-WeibelG: Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol2003; 23: 712–719.
6.
LewisGFRaderDJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res2005; 96: 1221–1232.
7.
FitzgeraldMLOkuhiraKShortGFIII: ATP-binding cassette transporter A1 contains a novel C-terminal VFVNFA motif that is required for its cholesterol efflux and ApoA-I binding activities. J Biol Chem2004; 279: 48477–48485.
8.
OramJF: HDL apolipoproteins and ABCA1: Partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol2003; 23: 720–727.
9.
AndoHTsuruokaSYamamotoH: Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther2004; 311: 420–425.
10.
ZanottiIFavariESpositoAC: Pitavastatin increases ABCA1-mediated lipid efflux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun2004; 321: 670–674.
11.
WongJQuinnCMBrownAJ: Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol2004; 24: 2365–2371.
12.
ArgmannCAEdwardsJYSawyezCG: Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: A role for RhoA in ABCA1-mediated cholesterol efflux. J Biol Chem2005; 280: 22212–22221.
13.
ZanottiIPotiFFavariE: Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: Evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP. J Pharm Exp Ther2006; 317: 395–401.
14.
AlexanderCMLandsmanPBTeutschSM: Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol2000; 86: 897–902.
15.
SaydahSHEberhardtMSLoriaCM: Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol2002; 156: 714–719.
16.
WindlerE: What is the consequence of an abnormal lipid profile in patients with type 2 diabetes or the metabolic syndrome?Atheroscler Suppl2005; 6: 11–14.
17.
KuchlerMSilverL: Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model. Biochem Biophys Res Commun2003; 305: 215–222.
18.
WangPRGuoQIppolitoM: High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur J Pharmacol2001; 427: 285–293.
19.
ContrerasJACastroMBocosC: Combination of an enzymatic method and HPLC for the quantitation of cholesterol in cultured cells. J Lipid Res1992; 33: 931–936.
20.
WangNSilverDLCostetP: Specific binding of ApoA1, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1. J Biol Chem2000; 275: 33053–33058.
21.
AnsellBJNavabMHamaS: Inflammatory/anti-inflammatory properties of high-density lipoprotein distinguish patients from coronary subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation2003; 108: 2751–2756.
22.
ZhengLNukunaBBrennanML: Apolipoprotein A-1 is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest2004; 114: 529–541.
23.
van LeuvenSIKasteleinJJ: Atorvastatin: Expert Opin Pharmacother2005; 6: 1191–1203.
24.
OkazakiSYokoyamaTMiyauchiK: Early statin treatment in patients with acute coronary syndrome: Demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: The ESTABLISH Study. Circulation2004; 110: 1061–1068.
25.
BortnickAERothblatGHStoudtG: The correlation of ATP binding cassette 1 mRNA levels with cholesterol efflux from various cell lines. J Biol Chem2000; 275: 28634–28640.
26.
LlaveriasGLacasaDVinalsM: Reduction of intracellular cholesterol accumulation in THP-1 macrophages by a combination of rosiglitazone and atorvastatin. Biochem Pharmacol2004; 68: 155–163.
27.
KumarAPReynoldsWF: Statins downregulate myeloperoxidase gene expression in macrophages. Biochem Biophys Res Commun2005; 331: 442–451.
28.
GhoshSSt ClairRWRudelLL: Mobilization of cytoplasmic CE droplets by overexpression of human macrophage cholesteryl ester hydrolase. J Lipid Res2003; 44: 1833–1840.
